Recent filings and disclosures have kept CVS Health Corp. in focus heading into late May 2026. The company operates across pharmacy benefits management, health services, and retail pharmacy segments, maintaining one of the largest healthcare distribution footprints in the United States. No material corporate announcements from briefings were available in the current context window beyond what is reflected in the regulatory filings noted below [Brief - 2026-05-27].
For the trailing twelve months ending 31 March 2026, CVS reported revenue of approximately $407.9 billion, representing 6.2% growth year-over-year. Net income over the same period stood at $2.93 billion, yielding a net margin of 0.72%. Gross margin was recorded at 7.19% and operating margin at 1.46%. The company held $9.54 billion in cash against total debt of $63.48 billion. The price-to-earnings ratio stood at 39.93, with EPS growing 63.1% year-over-year. Market capitalisation was approximately $115.9 billion at the period end [SEC 10-Q - CVS - 2026-03-31].
Insider activity in May 2026 is the primary trigger for this report. Across 16 recorded transactions during the month, the net direction of insider transactions was selling, with a combined net value of approximately -$323.7 million. This level of insider disposition activity over a 30-day window represents a notable volume of reported transactions by company insiders [SEC Form 4 - CVS - 2026-05].
The broader interest rate environment as of the generation date shows the 10-year US Treasury yield at 4.56% and the 2-year yield at 4.13%, producing a normal yield curve spread of approximately 43 basis points [FRED DGS10] [FRED DGS2]. For a company carrying $63.48 billion in total debt, prevailing rate levels remain a factor in ongoing debt servicing costs as reflected in reported financials.